These observations together support that serum anti-LIMS1 autoantibody could be used as a potential biomarker for pathologic myopia, which uncovers a previously unrecognized autoimmune etiology of MMD in pathologic myopia. This evidence concerns the gene LIMS1 and multiminicore myopathy.